228 related articles for article (PubMed ID: 29295989)
1. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.
Gibori H; Eliyahu S; Krivitsky A; Ben-Shushan D; Epshtein Y; Tiram G; Blau R; Ofek P; Lee JS; Ruppin E; Landsman L; Barshack I; Golan T; Merquiol E; Blum G; Satchi-Fainaro R
Nat Commun; 2018 Jan; 9(1):16. PubMed ID: 29295989
[TBL] [Abstract][Full Text] [Related]
2. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.
Xin X; Lin F; Wang Q; Yin L; Mahato RI
ACS Appl Mater Interfaces; 2019 Apr; 11(16):14647-14659. PubMed ID: 30933478
[TBL] [Abstract][Full Text] [Related]
3. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.
Chang W; Liu M; Xu J; Fu H; Zhou B; Yuan T; Chen P
Tumour Biol; 2016 Nov; 37(11):14813-14824. PubMed ID: 27638830
[TBL] [Abstract][Full Text] [Related]
4. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells.
Dong Q; Li C; Che X; Qu J; Fan Y; Li X; Li Y; Wang Q; Liu Y; Yang X; Qu X
Oncotarget; 2016 Dec; 7(50):82338-82353. PubMed ID: 27494897
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
7. HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.
He D; Huang C; Zhou Q; Liu D; Xiong L; Xiang H; Ma G; Zhang Z
Oncotarget; 2017 Mar; 8(12):20165-20178. PubMed ID: 28423622
[TBL] [Abstract][Full Text] [Related]
8. Amphiphilic poly(α)glutamate polymeric micelles for systemic administration of siRNA to tumors.
Krivitsky A; Polyak D; Scomparin A; Eliyahu S; Ofek P; Tiram G; Kalinski H; Avkin-Nachum S; Feiner Gracia N; Albertazzi L; Satchi-Fainaro R
Nanomedicine; 2018 Feb; 14(2):303-315. PubMed ID: 29127036
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor 2 mRNA binding protein 2 promotes aerobic glycolysis and cell proliferation in pancreatic ductal adenocarcinoma via stabilizing GLUT1 mRNA.
Huang S; Wu Z; Cheng Y; Wei W; Hao L
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):743-752. PubMed ID: 31089713
[TBL] [Abstract][Full Text] [Related]
10. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
Feng B; Wang R; Chen LB
Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
12. The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.
Shen H; Ye F; Xu D; Fang L; Zhang X; Zhu J
Cell Death Dis; 2021 Dec; 13(1):15. PubMed ID: 34930894
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer.
Li J; Ohmura S; Marchetto A; Orth MF; Imle R; Dallmayer M; Musa J; Knott MML; Hölting TLB; Stein S; Funk CM; Sastre A; Alonso J; Bestvater F; Kasan M; Romero-Pérez L; Hartmann W; Ranft A; Banito A; Dirksen U; Kirchner T; Cidre-Aranaz F; Grünewald TGP
Nat Commun; 2021 Sep; 12(1):5356. PubMed ID: 34531368
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms.
Long LM; Zhan JK; Wang HQ; Li S; Chen YY; Liu YS
Pathobiology; 2017; 84(1):38-48. PubMed ID: 27458977
[TBL] [Abstract][Full Text] [Related]
15. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
[TBL] [Abstract][Full Text] [Related]
16. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
17. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
18. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model.
Hu QL; Jiang QY; Jin X; Shen J; Wang K; Li YB; Xu FJ; Tang GP; Li ZH
Biomaterials; 2013 Mar; 34(9):2265-76. PubMed ID: 23298779
[TBL] [Abstract][Full Text] [Related]
19. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
